CL2022003012A1 - Anticuerpos anti-dectina-2 - Google Patents

Anticuerpos anti-dectina-2

Info

Publication number
CL2022003012A1
CL2022003012A1 CL2022003012A CL2022003012A CL2022003012A1 CL 2022003012 A1 CL2022003012 A1 CL 2022003012A1 CL 2022003012 A CL2022003012 A CL 2022003012A CL 2022003012 A CL2022003012 A CL 2022003012A CL 2022003012 A1 CL2022003012 A1 CL 2022003012A1
Authority
CL
Chile
Prior art keywords
methods
binding agents
dectin
inventive
nucleic acids
Prior art date
Application number
CL2022003012A
Other languages
English (en)
Spanish (es)
Inventor
Erin Ackerman Shelley
Dornan David
A Henning Karla
A Kenkel Justin
Original Assignee
Bolt Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolt Biotherapeutics Inc filed Critical Bolt Biotherapeutics Inc
Publication of CL2022003012A1 publication Critical patent/CL2022003012A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2022003012A 2020-05-01 2022-10-28 Anticuerpos anti-dectina-2 CL2022003012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063018952P 2020-05-01 2020-05-01

Publications (1)

Publication Number Publication Date
CL2022003012A1 true CL2022003012A1 (es) 2023-06-23

Family

ID=76076494

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003012A CL2022003012A1 (es) 2020-05-01 2022-10-28 Anticuerpos anti-dectina-2

Country Status (13)

Country Link
US (3) US11753474B2 (https=)
EP (1) EP4142881A1 (https=)
JP (1) JP2023524092A (https=)
KR (1) KR20230005907A (https=)
CN (1) CN115461122A (https=)
AU (1) AU2021262828A1 (https=)
BR (1) BR112022020639A2 (https=)
CA (1) CA3175576A1 (https=)
CL (1) CL2022003012A1 (https=)
CR (1) CR20220582A (https=)
IL (1) IL297782A (https=)
MX (1) MX2022013616A (https=)
WO (1) WO2021222894A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470424B1 (en) * 2016-06-08 2025-04-23 Shanghai Jiao Tong University School of Medicine Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2024216089A1 (en) * 2023-04-13 2024-10-17 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibody combination therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US7071171B1 (en) * 1996-12-20 2006-07-04 Board Of Regents The University Of Texas System Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2 compositions and uses thereof
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
BR112016014952A2 (pt) 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
WO2015143091A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
CN118108847A (zh) 2016-08-07 2024-05-31 诺华股份有限公司 mRNA介导的免疫方法
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CN111032087A (zh) * 2017-06-28 2020-04-17 小利兰·斯坦福大学托管委员会 用于dectin-2刺激和癌症免疫治疗的方法和组合物
AU2020253621A1 (en) 2019-04-05 2021-11-11 Dren Bio Management, Inc. Methods of depleting disease causing agents via antibody targeted phagocytosis
CA3198102A1 (en) 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof

Also Published As

Publication number Publication date
IL297782A (en) 2022-12-01
US12325750B2 (en) 2025-06-10
KR20230005907A (ko) 2023-01-10
US20220153849A1 (en) 2022-05-19
US20250270329A1 (en) 2025-08-28
BR112022020639A2 (pt) 2022-11-29
US20230406939A1 (en) 2023-12-21
WO2021222894A1 (en) 2021-11-04
CR20220582A (es) 2023-01-09
MX2022013616A (es) 2022-11-16
AU2021262828A1 (en) 2022-11-03
EP4142881A1 (en) 2023-03-08
CN115461122A (zh) 2022-12-09
US11753474B2 (en) 2023-09-12
JP2023524092A (ja) 2023-06-08
CA3175576A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
CL2022003012A1 (es) Anticuerpos anti-dectina-2
CO2022003582A2 (es) Métodos para el tratamiento de la oftalmopatía tiroidea
CL2020000252A1 (es) Muteínas de interleucina 21 y métodos de tratamiento.
CO2020015707A2 (es) Casetes de expresión de α-glucosidasa de ácido optimizado con codón y métodos de uso del mismo
BR112021023571A2 (pt) Enxerto de emplastro de células-tronco / progenitores em órgãos sólidos
CY1121857T1 (el) Ενωσεις οι οποιες επεκτεινουν αιμοποιητικα βλαστοκυτταρα
CL2020002161A1 (es) Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
BR112022011795A2 (pt) Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
BR112019008560A2 (pt) célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação
BR112022015969A2 (pt) Composições e métodos para enxerto de células editadas de base
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
MX2016010171A (es) Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas.
CL2022002276A1 (es) Composiciones y métodos para tratar discapacidad auditiva no asociada con la edad en un sujeto
ES2672895T3 (es) Generación de células T específicas de antígeno
GT200300180A (es) Vacunas para enfermedades reproductoras del ganado
MX2022008925A (es) Anticuerpos anti-pd-l1.
BRPI0618486A2 (pt) uso de células progenitoras multipotentes em adultos
MX2008007287A (es) Metodos y composiciones para expandir celulas reguladoras t.
CO2023001681A2 (es) Bancos de células t específicas para antígeno universal y métodos para producir y usar los mismos terapéuticamente
MX2021008772A (es) Composiciones y metodos para la estimulacion de celulas natural killer.
CO2023002959A2 (es) Neoantígenos ras y usos de los mismos
BR112022009204A2 (pt) Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70
BR112022009141A2 (pt) Terapia contra tumores sólidos cd70+ usando células t geneticamente manipuladas visando cd70
BR112023024434A2 (pt) Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas